For patients, caregivers, loved ones, advocates & healthcare specialists

At TYRA, we recognize that patients living with cancer and people living with genetically defined conditions are in desperate need of innovation from new therapies. This reality has inspired us to work “Tyrelessly” to advance next-generation product candidates with the goal to improve patient outcomes and quality of life.

Tyra Biosciences Current Clinical Trials

We are actively recruiting patients to participate in clinical trials to evaluate our therapeutic candidates. If you believe you or a loved one might be a good candidate for our trials, we encourage you to reach out directly through the link below.


TYRA-300 is an investigational FGFR3 inhibitor currently in clinical development initially for patients with locally advanced/metastatic urothelial carcinoma (bladder and urinary tract) and other solid tumors.  TYRA is currently enrolling patients in a Phase 1/2 clinical study of TYRA-300, (SURF301), a global study designed to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300.


The SURF201 study is currently enrolling and dosing adults with unresectable locally advanced/metastatic intrahepatic cholangiocarcinoma and other advanced solid tumors with activating FGFR2 gene alterations. The Phase 1 clinical study of TYRA-200, SURF201 (Study in PrevioUsly treated and Resistant FGFR2+ Cholangiocarcinoma and Other Advanced Solid Tumors) (NCT06160752), is a multi-center, open label study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of TYRA-200 and determine the optimal and maximum tolerated doses (MTD), as well as evaluate the preliminary antitumor activity of TYRA-200.

Reach Out

For questions or comments please reach out to us directly at [email protected]